{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265755","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.042590+00:00","generated_at":"2026-05-17T00:25:19.384699+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lexeo reports Q3 2025 net loss $20.3M; FDA open to accelerated BLA for LX2006; raised $154M equity","bullets":["FDA agreed to consider pooling ongoing Phase I/II LX2006 data with pivotal trial data for BLA; co-primary endpoint earlier than 12 months okayed.","FDA approved comparability between HEK293 and Sf9 manufacturing processes for LX2006; Sf9 process endorsed for pivotal study.","LX2006 interim data: 18-23% mean LVMI improvement at 6-12 months in abnormal-baseline patients; 2.0-point mean mFARS improvement (n=16).","Enrollment complete for LX2020 HEROIC-PKP2 Phase I/II (10 dosed); substantive data update expected January 2026.","Cash, equivalents, investments $122.8M at Sep 30, 2025; plus $153.8M net from October equity offering funds operations into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265755","json":"https://secwatch.observer/filing/0001193125-25-265755.json","markdown":"https://secwatch.observer/filing/0001193125-25-265755.md","text":"https://secwatch.observer/filing/0001193125-25-265755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/0001193125-25-265755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:25:19.384699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}